Mark Litton
2022 - Athira Pharma
In 2022, Mark Litton earned a total compensation of $3.8M as President and Chief Executive Officer at Athira Pharma, a 28% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $233,662 |
|---|---|
| Option Awards | $2,998,052 |
| Salary | $543,400 |
| Other | $85 |
| Total | $3,775,199 |
Litton received $3M in option awards, accounting for 79% of the total pay in 2022.
Litton also received $233.7K in non-equity incentive plan, $543.4K in salary and $85 in other compensation.
Rankings
In 2022, Mark Litton's compensation ranked 936th out of 5,736 executives tracked by ExecPay. In other words, Litton earned more than 83.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 936 out of 5,736 | 84th |
Division Manufacturing | 431 out of 3,125 | 86th |
Major group Chemicals And Allied Products | 156 out of 1,416 | 89th |
Industry group Drugs | 142 out of 1,317 | 89th |
Industry Biological Products, Except Diagnostic Substances | 33 out of 291 | 89th |
Source: SEC filing on April 5, 2023.
Litton's colleagues
We found two more compensation records of executives who worked with Mark Litton at Athira Pharma in 2022.